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Introduction
Drug-drug interactions are a recognised cause of morbidity 
and mortality worldwide.1 However, a PubMed search found 
only two studies that dealt with the occurrence of drug-drug 
interactions in primary health care from developing countries, 
namely a South African2 and a Mexican3 study. Adverse 
clinical effects due to drug-drug interactions occurring 
are often not recognised by healthcare practitioners and 
further medications are prescribed to treat these signs and 
symptoms. Clinically, it may be difficult to decide between 
drug interactions, side-effects or deterioration of the 
patient’s condition as the cause of the presenting clinical 
picture.4
The prevalence of potential drug-drug interactions ranges 
from 0.7-80%.2-6 Denmark has a highly computerised 
healthcare system. In a study in that country, 94.3% of 
prescriptions had one or more inappropriate ratings in 
terms of the Medication Appropriate Index,5 while only 
0.7% of these were due to potential drug-drug interactions 
occurring.5 Earlier studies found that four per cent of 
hospital admissions were due to drug-drug interactions6 
and a 12% prevalence of potential drug-drug interactions 
in primary health care.4 In contrast, a study of prescriptions 
issued to patients over 50 years of age in family medicine 
clinics in Mexico City revealed that 80% of scripts contained 
one or more potential drug-drug interactions and 3.8% had 
contraindicated drug combinations.3 
The only South African study listed in PubMed deals 
with potential drug-drug interactions and human 
immunodeficiency virus (HIV) drugs in a medical-aid 
database.2 Of 43 482 prescriptions analysed, 18 035 
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potential drug-drug interactions were found. However, this 
study excluded all anti-tuberculosis medications. No studies 
were found in PubMed or Medline that dealt specifically 
with the prevalence of potential drug-drug interactions in 
primary health care in South Africa as at 23 May 2011.
The responsible drugs vary worldwide, but four drug classes 
comprise 51% of interactions:7
•	 Antiplatelets: 16%
•	 Diuretics: 16%
•	 Nonsteroidal anti-inflammatory drugs (NSAIDs): 11%
•	 Anticoagulants: 8%.
Risk factors for drug-drug interactions are:
•	 Polypharmacy1,8
•	 Extremes of age (very young9 or elderly10)
•	 Multiple co-morbidities,1,8 especially cardiovascular 
disease3
•	 Increasing numbers of prescribing physicians.11
This study aimed to investigate the potential drug-drug 
interactions that could occur from the prescriptions issued 
at primary healthcare (PHC) clinics, to determine the 
prevalence of potential drug-drug interactions, which drugs 
were implicated, and to determine any other associations, 
such as specific diseases.
Method
Study design
A cross-sectional descriptive study was conducted of 
prescriptions from four PHC clinics (Sentrum, Pacaltsdorp, 
Conville and Thembelethu) in the George subdistrict, in the 
Eden district of the Western Cape. The study population 
was the patients who made use of PHC facilities at the 
above clinics from 1 February 2010-30 April 2010. Single 
drug scripts were excluded. No other inclusion or exclusion 
criteria were applied. 
Sampling
Simple random sampling was used. The sample size needed 
to estimate a proportion with a 95% confidence interval (CI) 
with precision of 5% (Cp = 5%), was determined by the 
statistician to be 385 scripts. Four hundred scripts were 
analysed from a cohort of 207 468 patient files.
Ethical considerations
Permission for the study was obtained from the University of 
Stellenbosch ethics committee, (N09/08/203) and from the 
Western Cape Department of Health (19/18/RP114/2009).
Data collection
Data were collected from the prescriptions from patients’ 
files and recorded in a password-protected database.  The 
variables included age, sex, all drugs prescribed concurrently 
during the period in question and chronic diseases that 
were recorded in the database. The data were transferred 
into a de-identified spreadsheet to protect the privacy of 
patients and prescribers. The drug lists were analysed using 
Medscape’s drug interaction checker for drug interactions12 
and verified using ePocrates® software. Each interaction 
was classified according to the Online Record of Clinical 
Activity (ORCA) classification.13,14 ORCA classification levels 
1-3 were identified and recorded as contraindicated, severe 
or moderate interactions. 
Statistical analysis
The data were analysed with support from the Centre for 
Statistical Consultation, Stellenbosch University, using 
Statistica® version 10. Summary statistics were presented 
using frequency tables, histograms, means and standard 
deviations. Comparisons of different subgroups were 
carried out using the chi-square test to compare nominal 
responses, and one-way analysis of variance (ANOVA) to 
compare continuous responses. Analysis was conducted to 
determine associations between chronic disease conditions 
and potential drug-drug interactions. Similarly, the 
relationship between patients’ age and potential drug-drug 
interactions, and between the numbers of drugs prescribed 
and drug-drug interactions, was determined. The impact of 
prescribers from the George hospital specialist departments 
was also examined. A significance level of 5% was used for 
all hypotheses tested.
Results
Of the 400 scripts analysed, 2 265 drugs were prescribed, 
which was an average of 5.66 drugs per script. One hundred 
and seventy-three scripts (43.25%) were found to have at 
least one potential drug-drug interaction. The prevalence 
Table I: Number of prescriptions containing potential drug-drug interactions at the four primary healthcare clinics
Site Scripts analysed (n) Moderate interactions Severe interactions Contraindicated 
combinations
Thembalethu 200 81 (40.5%) 5 (2.5%) 1 (0.5%)
Conville 65 24 (36.9%) 3 (4.6%) 0 (0%)
Sentrum 65 35 (53.9%) 9 (13.9%) 1 (1.5%)
Pacaltsdorp 70 28 (40%) 4 (5.7%) 0 (0%)
Total 400 168 (42%)* 21 (5.3%)** 2 (0.5%)***
The prevalence of prescriptions containing potential drug-drug interactions is given for each (in brackets) and according to the classification of potential drug-drug interactions.
*: chi-square (df = 3) = 4.68, p-value = 0.99660; **: chi-square (df = 3) = 10.63, p-value = 0.01392; chi-square (df = 3) = 2.26, p-value = 0.52055
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of prescriptions that contained moderate interactions 
was 42%, severe interactions 5.3%, and contraindicated 
combinations 0.5%. However, many prescriptions were 
found to contain more than one interaction. There were 
a total of 366 potential drug-drug interactions in the 400 
scripts analysed. Of these, 336 were potentially moderate 
drug-drug interactions, 28 severe, and two contraindicated 
combinations. Table I presents a breakdown of these 
findings.
The top 15 prescribed drugs are listed in Table II in 
descending order of frequency.
Figure 1 presents the drugs that were most commonly 
implicated in potential drug-drug interactions. Some drugs 
were implicated in more drug-drug interactions than the 
number of times that they were prescribed. For example, 
digoxin ranked 14 as a cause of potential drug-drug 
interactions. It was prescribed only four times, but was linked 
to 10 potential drug-drug interactions with furosemide, 
spironolactone, simvastatin and metoclopramide. Because 
these drugs are often prescribed together, it is easy to 
understand how digoxin had a 250% risk of being involved 
in a potential drug-drug interaction if it was prescribed. 
The most common interaction occurred between enalapril 
and aspirin (moderate interaction), with 86 occurrences. 
Hydrochlorothiazide was prescribed 109 times, but was 
only implicated in 18 potential drug-drug interactions.
Note to layout artist: Figure should be Times New Roman 
10 pt. Move the two little blocks (legend) beneath the figure 
and above the title
Table III represents the drugs that were implicated in 
potential drug-drug interactions more often than they were 
prescribed. Many of these were introduced by specialist 
departments from the local level 2 hospital. The final column 
represents the number of drug-drug interactions divided by 
the number of times that the drug was prescribed expressed 
as a percentage to indicate risk.
Table IV contains the top 20 prescribed drugs that were 



















































Figure 1: Top 10 causes of potential drug-drug interactions and the 
number of times they were prescribed
Table II: Top 15 drugs prescribed in descending order of frequency 
and the percentage of prescriptions containing that drug (n = 400)




1 Paracetamol 162 40.5
2 Aspirin 131 32.8
3 Enalapril 124 31
4 Hydrochlorothiazide 109 27.3
5 Amlodipine 99 24.8
6 Simvastatin 86 21.5
7 Ung methyl salicylate 77 19.3
8 Ibuprofen 71 17.8
9 Amoxicillin 63 15.8
10 Metformin 57 14.3
11 Atenolol 49 12.3
12 Amitriptyline 48 12
13 Vitamin B complex 45 11.3
14 Forosemide 40 10
15 Chlorpheniramine 37 9.3
Table III: Drugs at highest risk of being implicated in an interaction if prescribed
Ranking Drugs most likely to cause 
drug-drug interactions
Number of times prescribed Number of times implicated in 
a drug-drug interaction
Percentage of times 
implicated in a drug-
drug interaction vs. times 
prescribed
1 Digoxin 4 10 250
2 Amphotericin-B loz 1 2 200
3 Lamotrigine 1 2 200
4 Venlafaxine 1 2 200
5 Warfarin 12 21 175
6 Propranolol 2 3 150
7 Telmisarten 2 3 150
8 Fluoxetine 19 27 142.1
9 Losartan 3 4 133.3
10 Enalapril 124 161 129.8
Original Research: Sense of humour and adolescents’ cognitive flexibility
81 Vol 55 No 1S Afr Fam Pract 2013
exception was amlodipine which was prescribed 99 times, 
but was only implicated in a single potential drug-drug 
interaction with Titralac® (calcium carbonate). 
Severe interactions
Twenty-one prescriptions contained a total of 28 potentially 
severe drug-drug interactions. These were due to 15 
different interactions (Table V).
Warfarin and aspirin were implicated in 10 and six potentially 
severe drug-drug interactions, respectively (Figure 2).
Note to layout artist: Figure should be in Times New 
Roman 10 pt. Change allopurinol to Allopurinol. Change 
Amphotericin B to Amphotericin-B, close up the extra 
space between Potassium and choloride, change Valproic 
Acid to Valproic acid
Contraindicated combinations
Two instances of contraindicated combinations were found. 
Hyoscine butyl bromide plus oral potassium chloride were 

















































































































Figure 2: Drugs involved in severe interactions and the number of times they were implicated in a potential drug-drug interaction
Table IV: Drugs least likely to cause drug-drug interactions when prescribed
Amlodipine Cefixime Hydralazine
Ung methyl salicylate Doxazosin Cardura XL Stavudine
Amoxicillin Efavirenz Normal saline nose drops
Vit Bco Medroxyprogesterone acetate Promethazine
Chlorpheniramine Omeprazole Ipratropium bromide
Codeine Vidaylin/multivitamins Orphenadrine
Lamivudine Sorol citrate powder
Table V: Severe interactions
Severe drug interactions Occurrences
Warafin plus aspirin 6 (21.43%)
Fluoxetine plus clonazepam 3 (10.71%)
Tramadol plus amitriptyline 3 (10.71%)
Warfarin plus allopurinol 3 (10.71%)
Ferrous sulphate plus doxycycline 2 (7.14%)
Tramadol plus fluoxetine 2 (7.14%)
Allopurinol plus theophyllin 1 (3.57%)
Amphotericin-B plus anusol 1 (3.57%)
Amphotericin-B plus budesonide 1 (3.57%)
Ferrous sulphate plus ciprofloxacin 1 (3.57%)
Lamotrigine plus valproic acid 1 (3.57%)
Methotrexate plus diclofenac 1 (3.57%)
Quinine plus rifampicin 1 (3.57%)
Spironolactone plus potassium choloride 1 (3.57%)
Warfarin plus metronidazole 1 (3.57%)
The percentages are the percentage of all the potentially severe interactions caused by 
that combination.
Table VI: Chronic diseases and potential drug-drug interactions (total number of scripts n = 400)
Disease Number of patients 
diagnosed with
Percentage of scripts 
containing a potential 
drug-drug interaction
Percentage of scripts 
with a potentially severe 
drug-drug interaction
Average number of 
drugs per script
Hypertension 150 (37.5%) 72.7 6.7 7.2
Type 3 diabetes mellitus 58 (14.5%) 81 12.1 8.3
Human immunodeficiency virus 39 (9.8%) 38.5 2.6 7.7
Osteoarthritis 32 (8%) 81.3 6.3 8.9
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The investigated associations 
Diseases associated with drug-drug interactions
The top four diagnoses recorded in the files were 
hypertension, type 2 diabetes, HIV and osteoarthritis. 
These were examined to determine the percentage of 
scripts containing a potential drug-drug interaction. The 
percentage of scripts containing a potentially severe drug-
drug interaction was also determined (Table VI). 
The impact of prescribers at the George level 2 hospital
A total of 109 (27%) of the prescriptions had evidence of input 
from the George provincial hospital specialist departments. 
Of the 173 prescriptions that contained at least one drug-
drug interaction, 41% were adjusted at the George provincial 
hospital specialist department. Significantly more level 2 
interactions were found in the group of scripts that were 
influenced by George provincial hospital. Most (81%; 17/21) 
of the severe interactions related to this group of patients 
compared to 19% (4/21) that only had input from the PHC 
staff. This may be due to the effect of multiple prescribers 
and because these patients may have had more complex 
pathologies.
With regard to the group of scripts from George Hospital, 
63.3% (69/109) contained at least one moderate interaction. 
The group of scripts where all the drugs originated from the 
PHC clinics only contained a corresponding figure of 34% 
(99/291) for t (chi-square (degree of fredom = 1) = 27.77, 
p-value < 0.001). The prevalence of severe interactions in 
the regional hospital group was 16% (17/109), while the 
PHC only group was 1% (4/291). Each group had one 
contraindicated combination; George Hospital = 1/109 = 
0.9%, and PHC = 1/191 = 0.5% (Figure 3).
The impact of age
The mean age of the patients in the sample was 41 
years (95% CI, 39.3-43.3). The mean age for moderate 
interactions was 52.6 years (95% CI, 49.8-55.3); 52.5 years 
for severe interactions (95% CI, 43.8-61.2), and 67 years 
for contraindicated combinations (95% CI, 38.7-95.3). The 
mean ages did not differ significantly when tested with 
ANOVA where F (2.170) = 0.869 with p-value = 0.42 > 0.05. 
The impact of gender
Although 65.5% of the patients in the sample were female, 
gender was not associated with an increased risk of 
potential drug-drug interactions. For example, 43.13% of 
female and 43.48% of male scripts contained at least one 
potential drug-drug interaction.
The impact of polypharmacy on the number of drug-
drug interactions
The risk of being prescribed drugs that could have at least 
one potential drug-drug interaction increased with the 
number of drugs prescribed. The risk of being prescribed 
drugs that could have more than one potential drug-drug 
interaction was also increased. See Figure 4.
Note to layout artist:  Figure should be Times New Roman 
10 pt. Change Percentage At Least One DDI to % of patients 
who had at least one DDI. Change Percentage More than 
One DDI to % of patients who had more than one DDI. 
Remove The effect of polypharmacy from the figure as this 
is repeated in the title. Move the blocks (the legend) beneath 
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Discussion
Drug-drug interactions occur when the precipitant drug 
alters the effect of the object drug.6 Over 9 000 drug-drug 
interactions are recognised.15 Most are trivial. Only a few 
are clinically significant.10 The outcome may be harmful 
or fatal if the interaction increases toxicity or reduces the 
intended effect of the object drug.16 Some interactions are 
tolerated, e.g. enalapril plus low-dose aspirin. This is a 
moderate interaction which was responsible for 86 potential 
drug-drug interactions in this study. Aspirin antagonises the 
antihypertensive effect of angiotensin-converting enzyme 
inhibitors, increasing mean blood pressure.17-19 
The prevalence of potential drug-drug interactions found 
in the prescriptions in the George subdistrict was half that 
found in family medicine clinics in Mexico City where 80% 
of the scripts of elderly patients contained potential drug-
drug interactions.6 The prevalence of severe interactions 
in this study compares with a recent Spanish study which 
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Figure 3:  Prevalence of potential drug-drug interactions with input 
from George Hospital compared to potential drug-drug interactions 













Number of drugs prescribed
% of patients who had at least one DDI
% of patients who had more than one DDI
DDI: drug-drug interaction
The light blue area represents the percentage of prescriptions containing at least one 
potential drug-drug interaction for the number of drugs prescribed. The dark blue area is the 
percentage with more than one potential drug-drug interaction.
Figure 4: The effect of polypharmacy
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be 5.8% in a family medicine clinic.20 The most common 
drugs that were implicated were omeprazole, diazepam, 
warfarin, ibuprofen and calcium.20 In the present study, 
warfarin plus NSAIDs (aspirin, ibuprofen and diclofenac) 
featured prominently, as did benzodiazepines. By contrast, 
omeprazole was found to be safer. It was prescribed 13 
times and had no interactions (Table IV). 
The increasing risk of potential drug-drug interactions with 
increasing age and polypharmacy is well documented.3,10,21-24 
It was confirmed in this study. The relatively low risk of 
potential drug-drug interactions in patients who had been 
diagnosed with HIV was unexpected (Table VI). The average 
number of drugs per script (7.7) was higher than the number 
of drugs per script (5.7) of the sample. While only 38.5% 
of scripts had potentially moderate drug-drug interactions, 
only 2.6% of the scripts included a potentially severe drug-
drug interaction. Most patients were on regimen 1 of the 
South African national HIV guidelines25 which excludes 
protease inhibitors. In medical aid patients in South Africa, 
960 potential drug-drug interactions were found in 47 085 
prescriptions (2%).2 However, large numbers of patients 
were taking only one or two drugs which may explain the 
low prevalence of potential drug-drug interactions in that 
study. The scripts from files in which type 2 diabetes was 
diagnosed recorded the highest prevalence of potentially 
severe interactions (12.1%). The risk is amplified by altered 
pharmacokinetics as a result of disease factors, such as 
impaired renal function. Therefore, potential drug-drug 
interactions are more likely to manifest as clinical effects in 
these patients.
Drug-drug interactions are predictable and preventable. 
While the effects of moderate interactions should be 
noted, these seldom cause life-threatening complications. 
However, severe interactions require action to prevent harm. 
Contraindicated combinations should never be prescribed. 
It would seem prudent to provide some form of intervention 
to decrease the prevalence of severe and contra-
indicated interactions. While sophisticated technological 
advances have reduced the risk in first-world countries 
significantly,13,26,27 it is unlikely that the South African 
public healthcare service will embrace these technologies 
in the immediate future. Furthermore, electronic alerts are 
inconsistent, vary between products and are often ignored 
by prescribers and pharmacists.26-28
However, simple interventions, such as drug reviews 
and quality improvement cycles that focus on reducing 
potential drug-drug interactions, are effective and practical 
solutions.22 Improved communication between specialist 
departments and PHC clinics is also likely to have a positive 
effect.11 Regular medication reviews have been shown to 
substantially reduce the risk of drug-drug interactions 
and rationalise prescribing in patients with polypharmacy, 
reducing the number of prescribed medications by 20%.22 
The family physician may discover that dosages were 
modified and medications prescribed by other healthcare 
providers of which he or she was unaware. These reviews 
also enable identification of over-the-counter medications 
that the patient may be taking. Regular medication reviews 
would create awareness among prescribers and patients of 
the risks of polypharmacy, including drug-drug interactions. 
The identified risk factors in this study could be used to 
identify patients in PHC who should have a medication 
review. 
This includes prescribing:
•	 Drugs that are implicated in potential drug-drug 
interactions more often than they are prescribed 
(Table III).
•	 Drugs that commonly cause drug-drug interactions 
(Figure 1).
•	 Drugs that cause potentially severe interactions 
(Figure 2).
•	 More than five drugs per prescription (Figure 4).
•	 To patients who are older than 50 years.
•	 In the case of chronic diseases, such as type 2 diabetes, 
hypertension or osteoarthritis (Table VI).
•	 By specialist departments from the regional hospital 
(Figure 3).
It is likely that identifying these patients and exposing them 
to regular medication reviews by a team, including a family 
physician, pharmacist and clinical nurse practitioner, would 
be beneficial and cost-effective. Relying on memory, drug 
compendia or software alone is not effective.20
Limitations of this study
This study only detected potential interactions and relied 
on the accuracy of data that were recorded in the patients’ 
files. 
Drug-interaction checkers vary in their sensitivity and 
specificity.15 In instances in which different results were 
obtained from Medscape and ePocrates®, Medscape’s 
results were recorded. This was because the evidence 
that was provided was more detailed. New drug-drug 
interactions are continually being discovered. The results 
were correct as per Medscape’s interaction checker as at 
31 January 2011.
Although a number of comparisons were made from the 
study, the sample size was not calculated to give adequate 
power to all of these associations. For example, testing for 
associations was impossible because of the small number 
of contraindicated combinations.
Only four PHC sites were evaluated, although these 
probably reflect the broader population at risk of drug-drug 
interactions in PHC clinics in the Western Cape.
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Conclusion
Polypharmacy is rife. Patients receive up to 20 drugs per 
script. Potential drug-drug interactions are common. In 
this study, the overall prevalence of potential drug-drug 
interactions was 91.5%, while 43.25% of scripts contained 
at least one potential drug-drug interaction. More than five 
per cent of prescriptions contained a potentially severe 
interaction, and one in 200 scripts had a contraindicated 
combination. Simultaneous prescribing from a regional 
hospital increased the risk of script containing a potential 
drug-drug interaction. Common diseases such as 
hypertension, diabetes and osteoarthritis are the diagnoses 
that are most likely to be associated with potential drug-drug 
interactions. Polypharmacy was common in patients with 
HIV, but there were fewer potential drug-drug interactions. 
Warfarin and aspirin were the most common drugs that 
were implicated in potentially severe drug-drug interactions. 
The elderly are more likely to be given prescriptions that 
contain potential drug-drug interactions.
Recommendations
The prevalence of clinically significant events is presumed 
to be much lower than that illustrated by the figures in this 
study. However, these events are still likely to have significant 
consequences. By recognising this and implementing 
simple cost-effective mechanisms that aim to reduce 
potential drug-drug interactions, medical practitioners are 
likely to reduce the risk of drug-drug interactions in patients. 
Electronic media are expensive and drug compendia, 
clumsy. Identification of high-risk patients and evaluating 
their scripts as part of a regular medicine review, as well as 
improving communication between prescribing physicians, 
nurses and pharmacists, are measures that are likely to 
improve clinical governance and result in a decrease in the 
number of potential drug-drug interactions. The identified 
risk factors in this study included polypharmacy, elderly 
patients, multiple prescribers, the prescription of specific 
drugs and type 2 diabetes, hypertension and osteoarthritis. 
Scheduling these patients to have an annual medicine 
review may prove to be beneficial to them, while reducing 
the cost of drugs.
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